1. |
Cohen NM, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011; 4: 391-417.
|
|
2. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol 2013; 3: 1473-92.
|
|
3. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
|
|
4. Struwe WB, Warren CE. High-throughput RNAi screening for N-glycosylation dependent loci in Caenorhabditis elegans. Methods Enzymol 2010; 480: 477-93.
|
|
5. Lambeth LS, Van Hateren NJ, Wilson SA, et al. A direct comparison of strategies for combinatorial rna interference. BMC Mol Biol 2010; 11: 77.
|
|
6. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-51.
|
|
7. Yeom SY, Jeoung D, Ha KS, et al. Small interfering RNA (siRNA) targetted to Smad3 inhibits transforming growth factor-beta signaling. Biotechnol Lett 2004; 26: 699-703.
|
|
8. Xu J, Liu X, Koyama Y, et al. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front Pharmacol 2014; 5: 167.
|
|
9. Ota K, Quint P, Weivoda MM, et al. Transforming growth factor beta 1 induces CXCL16 and leukemia inhibitory factor expression in osteoclasts to modulate migration of osteoblast progenitors. Bone 2013; 57: 68-75.
|
|
10. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-72.
|
|
11. Kong D, Zhang F, Zhang Z, et al. Clearance of activated stellate cells for hepatic fibrosis regression: molecular basis and translational potential. Biomed Pharmacother 2013; 67: 246-50.
|
|
12. Fu MY, He YJ, Lv X, et al. Transforming growth factor-β1 reduces apoptosis via autophagy activation in hepatic stellate cells. Mol Med Rep 2014; 10: 1282-88.
|
|
13. Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-β family in wound healing, burns and scarring: a review. Int Burns Trauma 2012; 2: 18-28.
|
|
14. Moses HL, Branum EL, Proper JA, et al. Transforming growth factor production by chemically transformed cells. Cancer Res 1981; 41: 2842-48.
|
|
15. Kajdaniuk D, Marek B, Borgiel-Marek H, et al. Transforming growth factor β1 (TGFβ1) in physiology and pathology. Endokrynol Pol 2013; 64: 384-96.
|
|
16. Baghy K, Iozzo RV, Kovalszky I. Decorin-TGFβ axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 2012; 60: 262-68.
|
|
17. Suzuki C, Murakami G, Fukuchi M, et al. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem 2002; 277: 39919-25.
|
|
18. Finnson KW, McLean S, Di Guglielmo GM, et al. Dynamics of transforming growth factor beta signaling in wound healing and scarring. Adv Wound Care (New Rochelle) 2013; 2: 195-214.
|
|
19. Ozaki I, Hamajima H, Matsuhashi S, et al. Regulation of TGF-β1-induced pro-apoptotic signaling by growth factor receptors and extracellular matrix receptor integrins in the liver. Front Physiol 2011 Oct 24 [cited 2014 Sep 01]; 2: 78. Available from: http://journal.frontiersin.org/Journal/ 10.3389/fphys.2011.00078/full.
|
|
20. Tong Z, Chen R, Alt DS, et al. Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes. Hepatology 2009; 50: 939-47.
|
|
21. Huang JQ, Zhu J, Li L, et al. Expression of transforming growth factor-beta1 and connective tissue growing factor in schistosomal hepatic fibrosis of mice. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2012; 30: 20-6.
|
|
22. Guo YP, Yang GY, Wang JJ, et al. Expression of TGF-β1 and VEGF in forming course of hepatic fibrosis. Zhonghua Shi Yong Yu Zhen Duan Za Zhi 2008; 10: 724-25.
|
|
23. Liu CH, Xan HP. Effects of transforming growth factor beta1 on the proliferation and type I collagen expression at different differential rat hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 731-34.
|
|
24. Moore CB, Guthrie EH, Huang MT, et al. Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol 2010; 629: 141-58.
|
|
25. Ellermeier J, Wei J, Duewell P, et al. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res 2013; 73: 1709-20.
|
|
26. Li Y, Yang K, Mao Q, et al. Inhibition of TGF-beta receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase. Int Urol Nephrol 2010; 42: 315-23.
|
|
27. Hwang M, Kim HJ, Noh HJ, et al. TGF-beta1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol 2006; 81: 48-54.
|
|
28. Lang Q, Liu Q, Xu N, et al. The antifibrotic effects of TGF-β1 siRNA on hepatic fibrosis in rats. Biochem Biophys Res Commun 2011; 409: 448-53.
|
|
29. Sun YC, Liang Q, Qian KL, et al. Effect of TGF-β1 siRNA-mediated silencing on Smad proteins in hepatic fibrosis rats. Zhonghua Gan Zang Bing Za Zhi 2012; 20: 289-93.
|
|
30. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010; 9: 57-67.
|